Dr. Chris Armstrong

Dr. Chris Armstrong, CEO of Stem Cell Theranostics and expert in molecular biology, discusses innovative uses of iPSCs to model cardiovascular diseases. He explains how his company combines diagnostics with therapeutics to advance drug discovery. The conversation dives into techniques for screening therapies and assessing drug-induced cardiotoxicity. They also touch on the regulatory landscape around iPSC models, emphasizing their potential role in personalized medicine. Chris's journey from academia to biotech leadership adds a personal touch to the scientific insights.